IGF-1 and growth response to adult height in a randomized GH treatment trial in short non-GH-deficient children

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 8, 2014, Pages 2917-2924

  Kriström, Berit ^a,c   Lundberg, Elena ^a   Jonsson, Björn ^b   Albertsson Wikland, Kerstin ^c  

^a UMEÅ UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; BODY HEIGHT; CHILD; CHILD DEVELOPMENT; DWARFISM; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; TREATMENT OUTCOME;

EID: 84905841531     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1101     Document Type: Article

References (40)

1. Ranke MB. Towards a consensus on the definition of idiopathic short stature. Horm Res. 1996;45(suppl 2):64-66.
2. Wit JM, Reiter EO, Ross JL, et al. Idiopathic short stature: management and growth hormone treatment. Growth Horm IGF Res. 2008;18:111-135.
3. Albertsson-Wikland K, Aronson AS, Gustafsson J, et al. Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency. J Clin Endocrinol Metab. 2008;93:4342-4350.
4. Wit JM, Rekers-Mombarg LT, Cutler GB, et al. Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect. J Pediatr. 2005;146:45-53.
5. Kriström B, Aronson AS, Dahlgren J, et al. Growth Hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature. J Clin Endocrinol Metab. 2009;94:483-490.
6. Albertsson Wikland K, Kristrom B, Rosberg S, Svensson B, Nierop AF. Validated multivariate models predicting the growth response to GHtreatment in individual short children with a broad range inGH secretion capacities. Pediatr Res. 2000;48:475-484.
7. Carel JC, Ecosse E, Landier F, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab. 2012;97:416-425.
8. Albertsson-Wikland K, Sävendahl L, Mårtensson A, et al. Longterm mortality in patients with isolated GHD, ISS, and SGA treated with recombinantGHduring childhood in Sweden: application of a mortality model developed from the general population. Horm Res Paed. 2012;78:FC6-FC114.
9. Savendahl L, Maes M, Albertsson-Wikland K, et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab. 2012;97:E213-E217.
10. Cohen P, Bright GM, Rogol AD, Kappelgaard AM, Rosenfeld RG. Effects of dose and gender on the growth and growth factor response toGHin GH-deficient children: implications for efficacy and safety. J Clin Endocrinol Metab. 2002;87:90-98.
11. Rudman D, Moffitt SD, Fernhoff PM, McKenzie WJ, Kenny JM, Bain RP. The relation between growth velocity and serum somatomedin C concentration. J Clin Endocrinol Metab. 1981;52:622-627.
12. Albertsson-Wikland K, Hall K. Growth hormone treatment in short children: relationship between growth and serum insulin-like growth factor I and II levels. J Clin Endocrinol Metab. 1987;65: 671-678.
13. Blair JC, Camacho-Hubner C, Miraki Moud F, et al. Standard and low-dose IGF-I generation tests and spontaneous growth hormone secretion in children with idiopathic short stature. Clin Endocrinol (Oxf). 2004;60:163-168; discussion 161-162.
14. Kristrom B, Jansson C, Rosberg S, Albertsson-Wikland K. Growth response to growth hormone (GH) treatment relates to serum insulin- like growth factor I (IGF-I) and IGF-binding protein-3 in short children with variousGHsecretion capacities. Swedish Study Group for Growth Hormone Treatment. J Clin Endocrinol Metab. 1997; 82:2889-2898.
15. Kriström B, Albertsson-Wikland K. Serum insulin and IGF-I levels after 2 years of treatment with Individual GH doses (17-100 μg/kg = d) compared to standard dose (43 μg/kg = d) in prepubertal GHD and ISS children. Horm Res. 2009;72:256.
16. Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab. 2007;92:2480-2486.
17. Albertsson-Wikland K, Luo ZC, Niklasson A, Karlberg J. Swedish population-based longitudinal reference values from birth to 18 years of age for height, weight and head circumference. Acta Paediatr. 2002;91:739-754.
18. Karlberg J, Albertsson-Wikland K. Growth in full-term small-forgestational- age infants: from birth to final height. Pediatr Res. 1995; 38:733-739.
19. Niklasson A, Ericson A, Fryer JG, Karlberg J, Lawrence C, Karlberg P. An update of the Swedish reference standards for weight, length and head circumference at birth for given gestational age (1977- 1981). Acta Paediatr Scand. 1991;80:756-762.
20. Karlberg J. On the construction of the infancy-childhood-puberty growth standard. Acta Paediatr Scand. 1989;356(suppl):26-37.
21. Löfqvist C, Andersson E, Gelander L, Rosberg S, Blum WF, Albertsson Wikland K. Reference values for IGF-I throughout childhood and adolescence: a model that accounts simultaneously for the effect of gender, age, and puberty. J Clin Endocrinol Metab. 2001; 86:5870-5876.
22. Löfqvist C, Andersson E, Gelander L, et al. Reference values for insulin-like growth factor-binding protein-3 (IGFBP-3) and the ratio of insulin-like growth factor-I to IGFBP-3 throughout childhood and adolescence. J Clin Endocrinol Metab. 2005;90:1420-1427.
23. Albertsson-Wikland K, Rosberg S, Libre E, Lundberg LO, Groth T. Growth hormone secretory rates in children as estimated by deconvolution analysis of 24-h plasma concentration profiles. Am J Physiol. 1989;257:E809-E814.
24. Jansson C, Boguszewski C, Rosberg S, Carlsson L, Albertsson-Wikland K. Growth hormone (GH) assays: influence of standard preparations, GH isoforms, assay characteristics, and GH-binding protein. Clin Chem. 1997;43:950-956.
25. Kamp GA, Zwinderman AH, Van Doorn J, et al. Biochemical markers of growth hormone (GH) sensitivity in children with idiopathic short stature: individual capacity of IGF-I generation after high-dose GH treatment determines the growth response to GH. Clin Endocrinol (Oxf). 2002;57:315-325.
26. Counts DR, Silverman LA, Geffner ME, et al. A four-year, openlabel, multi-center, randomized, two-arm study of genotropin(R) in patients with idiopathic short stature: comparison of an individualized, target-driven treatment regimen to standard dosing of genotropin(R)-analysis of two-year data. Horm Res Paediatr. 2013;80:242-251.
27. Cohen P, Germak J, Rogol AD, Weng W, Kappelgaard AM, Rosenfeld RG. Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGFbased dosing study of short children. J Clin Endocrinol Metab. 2010;95:2089-2098.
28. Decker R, Nygren A, Kristrom B, et al. Different thresholds of tissuespecific dose-responses to growth hormone in short prepubertal children. BMC Endocr Disord. 2012;12:26.
29. Blum WF, Albertsson-Wikland K, Rosberg S, Ranke MB. Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab. 1993;76:1610-1616.
30. Blum WF, CotterillAM, Postel-VinayMC, Ranke MB, SavageMO, Wilton P. Improvement of diagnostic criteria in growth hormone insensitivity syndrome: solutions and pitfalls. Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes. Acta Paediatr. 1994;399(suppl): 117-124.
31. Thalange NK, Price DA, Gill MS, Whatmore AJ, Addison GM, Clayton PE. Insulin-like growth factor binding protein-3 generation: an index of growth hormone insensitivity. Pediatr Res. 1996;39: 849-855.
32. Selva KA, Buckway CK, Sexton G, et al. Reproducibility in patterns of IGF generation with special reference to idiopathic short stature. Horm Res. 2003;60:237-246.
33. Gelander L, Blum WF, Larsson L, Rosberg S, Albertsson-Wikland K. Monthly measurements of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in healthy prepubertal children: characterization and relationship with growth: the 1-year growth study. Pediatr Res. 1999;45:377-383.
34. Boguszewski M, Jansson C, Rosberg S, Albertsson-Wikland K. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age. J Clin Endocrinol Metab. 1996;81:3902-3908.
35. Dahlgren J, Albertsson-Wikland K. Final height in short children born small for gestational age treated with growth hormone. Pediatr Res. 2005;57:216-222.
36. Dahlgren J, Kristrom B, Niklasson A, Nierop AF, Rosberg S, Albertsson- Wikland K. Models predicting the growth response to growth hormone treatment in short children independent of GH status, birth size and gestational age. BMC Med Inform Decis Mak. 2007;7:40.
37. Wit JM, Ranke MB, Albertsson-Wikland K, et al. Personalized approach to growth hormone treatment: clinical use of growth prediction models. Horm Res Paediatr. 2013;79:257-270.
38. Kriström B, Albertsson-Wikland K.Growthprediction models, concept and use. Horm Res. 2002;57(suppl 2):66-70.
39. Kriström B, Dahlgren J, Niklasson A, Nierop AF, Albertsson-Wikland K. The first-year growth response to growth hormone treatment predicts the long-term prepubertal growth response in children. BMC Med Inform Decis Mak. 2009;9:1.
40. RankeMB, Lindberg A, Chatelain P, et al. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. J Clin Endocrinol Metab. 1999;84:1174-1183.